Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab

NCT01564914 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT01564914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
June 30, 2015
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme